- Home
- FNA vs QURE Comparison
FNA vs QURE Comparison
Compare FNA & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNA
- QURE
- Stock Information
- Founded
- FNA 2010
- QURE 1998
- Country
- FNA United States
- QURE Netherlands
- Employees
- FNA N/A
- QURE N/A
- Industry
- FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- FNA Health Care
- QURE Health Care
- Exchange
- FNA Nasdaq
- QURE Nasdaq
- Market Cap
- FNA 852.1M
- QURE 750.6M
- IPO Year
- FNA 2021
- QURE 2007
- Fundamental
- Price
- FNA $10.70
- QURE $16.65
- Analyst Decision
- FNA Strong Buy
- QURE Strong Buy
- Analyst Count
- FNA 5
- QURE 8
- Target Price
- FNA $15.60
- QURE $30.43
- AVG Volume (30 Days)
- FNA 550.3K
- QURE 4.6M
- Earning Date
- FNA 11-12-2024
- QURE 11-05-2024
- Dividend Yield
- FNA N/A
- QURE N/A
- EPS Growth
- FNA N/A
- QURE N/A
- EPS
- FNA N/A
- QURE N/A
- Revenue
- FNA $244,995,000.00
- QURE $28,587,000.00
- Revenue This Year
- FNA $18.58
- QURE $150.65
- Revenue Next Year
- FNA $14.85
- QURE N/A
- P/E Ratio
- FNA N/A
- QURE N/A
- Revenue Growth
- FNA 18.16
- QURE N/A
- 52 Week Low
- FNA $4.65
- QURE $3.73
- 52 Week High
- FNA $14.79
- QURE $17.71
- Technical
- Relative Strength Index (RSI)
- FNA 60.03
- QURE 78.10
- Support Level
- FNA $10.19
- QURE $6.11
- Resistance Level
- FNA $11.00
- QURE $17.71
- Average True Range (ATR)
- FNA 0.51
- QURE 1.32
- MACD
- FNA -0.13
- QURE 0.94
- Stochastic Oscillator
- FNA 43.20
- QURE 88.41
About FNA Paragon 28 Inc.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.